Page 120 - 《中国药房》2025年3期
P. 120

lizes hyperglycemia caused by the tacrolimus-induced gut   suppressive agents[J]. Chin J Hosp Pharm,2020,40(22):
               microbiota[J]. Am J Transplant,2020,20(9):2413-2424.  2377-2381.
          [13]  ROOKS M G,GARRETT W S. Gut microbiota,metabo‐  [25]  SAVAGE N. The complex relationship between drugs and
               lites  and  host  immunity[J].  Nat  Rev  Immunol,2016,16  the microbiome[J]. Nature,2020,577(7792):S10-S11.
              (6):341-352.                                    [26]  GUO Y K,CRNKOVIC C M,WON K J,et al. Commen‐
          [14]  YUAN J J,CHANG X N,LI M,et al. Clinical utility of   sal gut bacteria convert the immunosuppressant tacrolimus
               characterizing  intestinal  flora  in  septic  kidney  injury[J].   to less potent metabolites[J]. Drug Metab Dispos,2019,47
               Chin Med J (Engl),2020,133(7):842-846.             (3):194-202.
          [15]  陈刚,陈志东,蒋文涛,等. 中国肝、肾移植受者霉酚酸类                   [27]  GUO Y K,LEE H,EDUSEI E,et al. Blood profiles of gut
               药物应用专家共识:2023版[J]. 上海医药,2023,44(19):                bacterial  tacrolimus  metabolite  in  kidney  transplant  reci-
               3-19,47.                                            pients[J]. Transplant Direct,2020,6(10):e601.
               CHEN G,CHEN Z D,JIANG W T,et al. Expert consen‐  [28]  SIMPSON  J  B,SEKELA  J  J,GRABOSKI  A  L,et  al.
               sus on the use of mycophenolic acid in Chinese liver and   Metagenomics  combined  with  activity-based  proteomics
               kidney  transplant  recipients:2023  edition[J].  Shanghai   point to gut bacterial enzymes that reactivate mycopheno‐
               Med Pharm J,2023,44(19):3-19,47.                    late[J]. Gut Microbes,2022,14(1):2107289.
          [16]  JARDOU M,PROVOST Q,BROSSIER C,et al. Altera‐  [29]  COHEN I,RUFF W E,LONGBRAKE E E. Influence of
               tion of the gut microbiome in mycophenolate-induced en‐  immunomodulatory drugs on the gut microbiota[J]. Transl
               teropathy:impacts on the profile of short-chain fatty acids   Res,2021,233:144-161.
               in  a  mouse  model[J].  BMC  Pharmacol  Toxicol,2021,  [30]  TAYLOR M R,FLANNIGAN K L,RAHIM H,et al. Van‐
               22(1):66.                                           comycin relieves mycophenolate mofetil-induced gastroin‐
          [17]  SHI  W  Y,LI  Z  J,WANG  W  D,et  al.  Dynamic  gut   testinal toxicity by eliminating gut bacterial β-glucuroni‐
               microbiome-metabolome  in  cationic  bovine  serum  albu‐  dase activity[J]. Sci Adv,2019,5(8):eaax2358.
               min induced experimental immune-complex glomerulone‐  [31]  WANG  J  J,ZHU  N  N,SU  X  M,et  al.  Gut-microbiota-
               phritis  and  effect  of  losartan  and  mycophenolate  mofetil   derived metabolites maintain gut and systemic immune ho‐
               on microbiota modulation[J]. J Pharm Anal,2024,14(4):  meostasis[J]. Cells,2023,12(5):793.
               100931.                                        [32]  KUMAR P,MONIN L,CASTILLO P,et al. Intestinal in‐
          [18]  FLANNIGAN K L,TAYLOR M R,PEREIRA S K,et al.        terleukin-17 receptor signaling mediates reciprocal control
               An  intact  microbiota  is  required  for  the  gastrointestinal   of  the  gut  microbiota  and  autoimmune  inflammation[J].
               toxicity of the immunosuppressant mycophenolate mofetil  Immunity,2016,44(3):659-671.
               [J]. J Heart Lung Transplant,2018,37(9):1047-1059.  [33]  YANG  W  J,YU  T  M,HUANG  X  S,et  al.  Intestinal
          [19]  WANG M Z,ZHU Z Y,LIN X Y,et al. Gut microbiota     microbiota-derived  short-chain  fatty  acids  regulation  of
               mediated the therapeutic efficacies and the side effects of   immune  cell  IL-22  production  and  gut  immunity[J].  Nat
               prednisone in the treatment of MRL/Lpr mice[J]. Arthritis   Commun,2020,11(1):4457.
               Res Ther,2021,23(1):240.                       [34]  KANDIKATTU H K,VENKATESHAIAH S U,VERMA
          [20]  ZHANG J,FENG D,LAW H K,et al. Integrative analysis   A K,et al. Tacrolimus (FK506) treatment protects aller‐
               of gut microbiota and fecal metabolites in rats after predni‐  gen- ,IL-5-  and  IL-13-induced  mucosal  eosinophilia[J].
               sone treatment[J]. Microbiol Spectr,2021,9(3):e0065021.  Immunology,2021,163(2):220-235.
          [21]  GIOCO R,CORONA D,EKSER B,et al. Gastrointestinal   [35]  MEYER  N,BRODOWSKI  L,VON  KAISENBERG  C,
               complications after kidney transplantation[J]. World J Gas‐  et  al.  Cyclosporine  A  and  tacrolimus  induce  functional
               troenterol,2020,26(38):5797-5811.                   impairment  and  inflammatory  reactions  in  endothelial
          [22]  VAN G T. How cyclosporine reduces mycophenolic acid   progenitor cells[J]. Int J Mol Sci,2021,22(18):9696.
               exposure by 40% while other calcineurin inhibitors do not  [36]  JOVER R,BORT R,JOSÉ GÓMEZ-LECHÓN M,et al.
               [J]. Kidney Int,2021,100(6):1185-1189.              Down-regulation of human CYP3A4 by the inflammatory
          [23]  VICENTINI F A,KEENAN C M,WALLACE L E,et al.        signal  interleukin-6:molecular  mechanism  and  transcrip‐
               Intestinal microbiota shapes gut physiology and regulates   tion  factors  involved[J].  FASEB  J,2002,16(13):1799-
               enteric neurons and glia[J]. Microbiome,2021,9(1):210.  1801.
          [24]  周锦屏,张蕊,刘亚妮,等. 肠道菌群与免疫抑制剂相互                    [37]  XIE Y,HU F D,XIANG D W,et al. The metabolic effect
               作用研究进展[J]. 中国医院药学杂志,2020,40(22):                    of gut microbiota on drugs[J]. Drug Metab Rev,2020,52
               2377-2381.                                         (1):139-156.
               ZHOU J P,ZHANG R,LIU Y N,et al. Advances in the              (收稿日期:2024-07-18  修回日期:2024-12-27)
               study of interaction between intestinal flora and immuno‐                          (编辑:胡晓霖)


          · 366 ·    China Pharmacy  2025 Vol. 36  No. 3                               中国药房  2025年第36卷第3期
   115   116   117   118   119   120   121   122   123   124   125